Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: January 27, 2023

Details for Patent: 8,071,623

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,071,623 protect, and when does it expire?

Patent 8,071,623 protects ZEJULA and is included in one NDA.

This patent has eighty-one patent family members in forty-nine countries.

Summary for Patent: 8,071,623
Title:Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Abstract: The present invention relates to compounds of formula I: ##STR00001## and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and/or radiosensitizers for cancer treatment.
Inventor(s): Jones; Philip (Rome, IT), Ontoria Ontoria; Jesus Maria (Rome, IT), Scarpelli; Rita (Rome, IT), Schultz-Fademrecht; Carsten (Rome, IT)
Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti SpA (Rome, unknown)
Application Number:12/006,993
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,071,623

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,071,623

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0700432.8Jan 10, 2007

International Family Members for US Patent 8,071,623

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 064777 See Plans and Pricing
Austria 502933 See Plans and Pricing
Australia 2007232297 See Plans and Pricing
Australia 2008204380 See Plans and Pricing
Brazil PI0806245 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.